TMCnet News
Castle Creek Pharmaceuticals Continues to Build Executive Team as Company Secures Funding, Positive Phase 2 ResultsCastle Creek Pharmaceuticals (CCP), a rapidly growing biopharmaceutical company with a focus on the treatment of patients with rare and debilitating dermatologic and head and neck conditions, today announced key leadership hires to accommodate the company's expansion. CCP recently raised $48 million in funding from Fidelity Management and Research Company and presented positive data from a Phase 2 study evaluating the efficacy and safety of topical diacerein 1% in patients with Epidermolysis Bullosa Simplex (EBS). "Castle Creek has rapidly assembled a robust and diversified late-stage pipeline of innovative and high-potential products with a particular focus on rare diseases and other areas of high medical need," said Michael Derby, CEO of CCP. "We are thrilled to have such a talented and entrepreneurial team with deep experience in dermatology and rare disease and a shared vision on meeting patient needs with life changing drugs." Castle Creek's executive team now includes:
The company recently moved into its new headquarters in Parsippany, New Jersey. For more information, visit: www.castlecreekpharma.com. About Castle Creek Pharmaceuticals Castle Creek Pharma is a high-growth biopharmaceutical company that has rapidly assembled a robust and diversified late-stage pipeline of products backed by strong science and focused on meeting patient needs in the treatment of rare and debilitating dermatologic and head and neck conditions.
Web| www.castlecreekpharma.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161101005728/en/ |